

In-person and Virtual



NOVARTIS Satellite Symposium

of Breast Cancer"

DATEFriday, April 9th, 2021TIME13:10 - 13:55



Topic

Are all CDK 4/6 Inhibitors Created Equally?

Chairperson

Keun Seok Lee MD, PhD

National Cancer Center, S.Korea

Speaker

Yen-Shen Lu MD, PhD

National Taiwan University Hospital, Taipei, Taiwan



Keun Seok Lee, MD, PhD National Cancer Center, S.Korea

- Head, Center for Clinical Trials, National Cancer Center
- Director, Insurance & Policy Committee, Korean Society of Medical Oncology
- As a medical oncologist specializing in the care of patients with breast cancer, Dr. Lee is actively participating in many international and domestic clinical trials.

Speaker



Yen-Shen Lu, MD, PhD

National Taiwan University Hospital, Taipei, Taiwan

- Clinical Professor in the Department of Internal Medicine, at the National Taiwan University (NTU) College of Medicine in Taipei, Taiwan, and serves as an Attending Physician at the Department of Oncology, NTU Hospital.
- Dr. Lu has vast experience as a study initiator, protocol writer, and principal investigator or co-principal investigator for more than 50 clinical trials, with particular emphasis on targeted agents in metastatic breast cancer. Dr. Lu published extensively with nearly 100 peer-reviewed articles published in journals. He received the Scholar in Training Award at the 92nd Annual Meeting of the AACR.
- Dr. Lu co-chaired MONALEESA-7 global study. He is the corresponding author of the M-7 PFS article and the co-first author of the M-7 OS article. He is one of the leading global medical expert from Asia for BC, particularly on premenopausal BC topics.